We track 17 channels and verify prices on a schedule. Start with the True-Cost Index for what things cost, or the medication guides below for what they are.
Head-to-head pages computed from the same data: every comparison we publish, or jump to the Hims vs Ro and Cora vs Trimi matchups. Provider dossiers with trust files live at /providers/.
The medication is scaffolding. Eating on a GLP-1 covers the protein targets and resistance work the trials point to — the part that decides whether results survive the last dose.
The complaint targets sharing sensitive health data with ad platforms and ROSCA billing/cancellation practices — context for anyone weighing the $149/month membership model.
The Hims dossier →Participating Part D plans now cover Wegovy (pen and pill), Foundayo, and the Zepbound KwikPen at a flat $50 monthly copay through 2027 — below every cash price we track.
How the Bridge actually works →The proposed 503B Bulks List exclusion would close the mass-compounding era for good. Patient-specific 503A compounding continues — the legal market our index tracks at $139–$297 all-in.
The surviving market, explained →Lilly's once-daily oral launched via LillyDirect at $149–$349/month by dose, with promo tiers through 2026.
Every Foundayo price →All tracked news → · Fed by a daily automated scan; entries publish only after primary-source verification.